Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.
Click through for clinical trial updates and expert reaction to the SURPASS and SURMOUNT phase 3 trials of the novel dual-action medication tirzepatide in people with type 2 diabetes and/or obesity.
How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.
Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this patient case study.
US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26).
Phase 3 trials of tirzepatide in type 2 diabetes and obesity
Read our overview of the SURPASS trials of the dual GLP-1/GIP receptor agonist tirzepatide in people with type 2 diabetes, plus the SURMOUNT trials in people with obesity.